Earnings Release • Aug 7, 2025
Earnings Release
Open in ViewerOpens in native device viewer
Ad hoc announcement pursuant to Art. 53 LR
Galenica AG / Key word(s): Half Year Results
Galenica demonstrates pleasing growth and improves EBIT guidance
07-Aug-2025 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Galenica recorded pleasing growth in a positive market environment in the first half of 2025. Both the “Products & Care” segment (+4.6%) and the “Logistics & IT” segment (+5.5%) contributed to the increase in sales of 5.0% to CHF 1,995.4 million. As a result, Galenica Group sales grew slightly stronger than the pharmaceutical market (+4.8% 2 ) and the consumer healthcare market (+0.6% 3 ).
Following an increase of 4.7% by the end of April 2025, Galenica Group sales increased further in May and June 2025. Growth in the first half of the year was driven by strong demand for prescription drugs, including GLP-1-based 4 weight loss products, as well as drugs associated with the heavy flu season early in the year. The good result was achieved despite one less day of sales compared to the same period in the previous year.
Reported EBIT increased by 6.2% to CHF 108.8 million, while adjusted EBIT 1 increased by 10.9% to CHF 109.9 million. In the first half of 2025, EBIT was supported by the pleasing sales growth as well as by positive one-off effects in the amount of CHF 5.4 million. Without these effects, adjusted EBIT 1 would have increased by 5.4%. The reason for this is that fines in two competition proceedings were significantly lower than originally expected, positively impacting the “Logistics & IT” segment.
Galenica confirms its 2025 outlook for consolidated net sales with growth of between 3% and 5% and the dividend at least at the same level as the previous year. Due to the strong growth in the first half of the year and positive one-time effects of CHF 5.4 million, Galenica now expects an EBIT 1 increase of between 7% and 9%. Prior to this, growth of between 4% and 6% had been expected.
In early July 2025, Galenica announced the acquisition of the diagnostics service provider Labor Team. As the closing date of the transaction has not yet been determined, the Labor Team Group is not yet included in the 2025 guidance .
| (in million CHF) | 1st half of 2025 | 1st half of 2024 | Change |
|---|---|---|---|
| Net sales | |||
| Products & Care segment | 867.3 | 829.3 | +4.6% |
| Retail (B2C) | 731.1 | 695.4 | +5.1% |
| Local Pharmacies | 693.1 | 657.6 | +5.4% |
| Pharmacies at Home | 38.1 | 37.9 | +0.3% |
| Professionals (B2B) | 140.9 | 138.4 | +1.8% |
| Products & Brands | 97.8 | 97.0 | +0.9% |
| Services for Professionals | 43.1 | 41.4 | +4.0% |
| Logistics & IT segment | 1,649.7 | 1,563.3 | +5.5% |
| Wholesale | 1,579.6 | 1,496.5 | +5.6% |
| Logistics & IT Services | 83.0 | 77.7 | +6.9% |
| Corporate and eliminations | -521.7 | -492.6 | |
| Galenica Group | 1,995.4 | 1,900.0 | +5.0% |
| EBIT adjusted 1 | |||
| Products & Care segment | 79.5 | 75.9 | +4.6% |
| Logistics & IT segment | 32.0 | 25.4 | +25.8% |
| Corporate and eliminations | -1.6 | -2.2 | |
| Galenica Group | 109.9 | 99.1 | +10.9% |
| Net profit from ongoing business activities adjusted 1 | 90.7 | 77.7 | +16.8% |
1) Excluding the effects of IFRS 16 and IAS 19 (details of the adjusted key figures in the half year report 2025 )
2) IQVIA, Pharmaceutical Market Switzerland, YTD June 2025.
3) IQVIA, Consumer Health Market Switzerland, YTD June 2025.
4) GLP-1 stands for glucagon-like peptide 1, a hormone produced in the intestine and which plays an important role in regulating blood sugar levels.
Conference call at 2 p.m.
Galenica will host a Zoom Conference Call on the results for the first half of 2025 today, Thursday, 7 August 2025, at 2 p.m. (CEST). You can follow the Zoom conference via this link: Zoom conference (meeting: 880 3349 4358, code: 2466)
The conference will be held in German with simultaneous English interpreting. The presentation will be available on the website from around 12 noon (CEST) on 7 August 2025. A recording of the conference call will then be made available on the website .
Upcoming dates
23 October 2025: Galenica Group sales update
28 October 2025: Galenica Investor Day 2025
22 January 2026: Galenica Group sales update
For further information, please contact:
| Media Relations: Tel. +41 58 852 85 17 E-Mail: [email protected] |
Investor Relations: Tel. +41 58 852 85 31 E-Mail: [email protected] |
Welcome to the Galenica network!
Around 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally.
Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com .
End of Inside Information
| Language: | English |
| Company: | Galenica AG |
| Untermattweg 8 | |
| 3027 Bern | |
| Switzerland | |
| Phone: | +41 058 852 81 11 |
| E-mail: | [email protected] |
| Internet: | https://www.galenica.com |
| ISIN: | CH0360674466 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2180242 |
| End of Announcement | EQS News Service |
2180242 07-Aug-2025 CET/CEST
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.